Regavirumab
Regavirumab
Regavirumab (pronunciation: /rɛɡəˈvɪrʊmæb/) is a monoclonal antibody designed for the treatment of various types of cancer.
Etymology
The name "Regavirumab" is derived from the Latin words "regavi" meaning "I have ruled" and "virumab" which is a common suffix for monoclonal antibodies.
Usage
Regavirumab is used in the treatment of various types of cancer, including colorectal cancer, gastric cancer, and lung cancer. It works by blocking the action of a certain protein in the body that helps cancer cells grow and divide.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Colorectal cancer: A cancer that starts in the colon or the rectum.
- Gastric cancer: Also known as stomach cancer, it's a disease in which malignant (cancer) cells form in the lining of the stomach.
- Lung cancer: A type of cancer that begins in the lungs.
Side Effects
Like all medications, Regavirumab can cause side effects. Common side effects include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include hypertension, bleeding, and infection.
External links
- Medical encyclopedia article on Regavirumab
- Wikipedia's article - Regavirumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski